A. Stephenson, M. Kattan, and J. Eastham, Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition, Journal of Clinical Oncology, vol.24, issue.24, pp.3973-3981, 2006.
DOI : 10.1200/JCO.2005.04.0756

R. Attar, C. Takimoto, and M. Gottardis, Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes, Clinical Cancer Research, vol.15, issue.10, pp.3251-3256, 2009.
DOI : 10.1158/1078-0432.CCR-08-1171

D. Petrylak, C. Tangen, and M. Hussain, Docetaxel and estramustine 28 Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group, J Clin Oncol, vol.17, pp.3461-3468, 1999.

R. Sramkoski, T. Pretlow, . Ii, and J. Giaconia, A new human prostate carcinoma cell line, 22Rv1, In Vitro Cellular & Developmental Biology - Animal, vol.54, issue.7, pp.403-412, 1999.
DOI : 10.1007/s11626-999-0115-4

D. Mickey, K. Stone, H. Wunderli, G. Mickey, and D. Paulson, Characterization of a human prostate adenocarcinoma cell line (DU 145) as a monolayer culture and as a solid tumor in athymic mice, Prog Clin Biol Res, vol.37, pp.67-84, 1980.

L. Cindolo, M. Cantile, F. Vacherot, S. Terry, A. De-la-taille et al., Neuroendocrine Differentiation in Prostate Cancer: From Lab to Bedside, Neuroendocrine-like prostate cancer cells, pp.287-96, 2007.
DOI : 10.1159/000109711

D. Amico, A. Whittington, R. Malkowicz, and S. , Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer, JAMA, vol.280, issue.11, pp.969-74, 1998.
DOI : 10.1001/jama.280.11.969

J. Walz, F. Chun, and E. Klein, Nomogram Predicting the Probability of Early Recurrence After Radical Prostatectomy for Prostate Cancer, The Journal of Urology, vol.181, issue.2, pp.601-608, 2009.
DOI : 10.1016/j.juro.2008.10.033

C. Burkhart, M. Kavallaris, B. Horwitz, and S. , The role of beta-tubulin isotypes in resistance to antimitotic drugs, Biochim Biophys Acta, vol.1471, pp.1-9, 2001.

M. Kavallaris, C. Burkhart, S. Horwitz, K. Akasaka, C. Maesawa et al., Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol Loss of class III beta-tubulin induced by histone deacetylation is associated with chemosensitivity to paclitaxel in malignant melanoma cells, Br J Cancer J Invest Dermatol, vol.80129, issue.37, pp.1020-51516, 1999.

K. Kamath, L. Wilson, F. Cabral, and M. Jordan, ??III-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability, Journal of Biological Chemistry, vol.280, issue.13, pp.12902-12909, 2005.
DOI : 10.1074/jbc.M414477200

P. Seve, S. Isaac, and O. Tredan, Expression of Class III ??-Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy, Clinical Cancer Research, vol.11, issue.15, pp.5481-5487, 2005.
DOI : 10.1158/1078-0432.CCR-05-0285

M. Hari, H. Yang, C. Zeng, M. Canizales, and F. Cabral, Expression of class III ?-tubulin reduces microtubule assembly and confers resistance to paclitaxel, Cell Motility and the Cytoskeleton, vol.10, issue.1, pp.45-56, 2003.
DOI : 10.1002/cm.10132

S. Mozzetti, C. Ferlini, and P. Concolino, Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients, Clin Cancer Res, vol.11, pp.298-305, 2005.

C. Stengel, S. Newman, M. Leese, B. Potter, M. Reed et al., Class III ??-tubulin expression and in vitro resistance to microtubule targeting agents, British Journal of Cancer, vol.8, issue.2, pp.316-340
DOI : 10.1016/S0169-5002(01)00291-4

P. Gan, E. Pasquier, and M. Kavallaris, Class III ??-Tubulin Mediates Sensitivity to Chemotherapeutic Drugs in Non Small Cell Lung Cancer, Cancer Research, vol.67, issue.19, pp.9356-63, 2007.
DOI : 10.1158/0008-5472.CAN-07-0509

K. Blade, D. Menick, and F. Cabral, Overexpression of class I, II or IVb

P. Gan and M. Kavallaris, Tubulin-Targeted Drug Action: Functional Significance of Class II and Class IVb ??-Tubulin in Vinca Alkaloid Sensitivity, Cancer Research, vol.68, issue.23, pp.9817-9841, 2008.
DOI : 10.1158/0008-5472.CAN-08-1501

E. Thomas, J. Tabernero, and M. Fornier, Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer, Journal of Clinical Oncology, vol.25, issue.23, pp.3399-406, 2007.
DOI : 10.1200/JCO.2006.08.9102